Table 3.
Prognostic factors by univariate and multivariate analyses
| Pre-PSM | Post-PSM | |||||
|---|---|---|---|---|---|---|
| univariate analyses | multivariate analyses | multivariate analyses | ||||
| P | HR(95% CI) | P | HR(95% CI) | P | HR(95% CI) | |
| Gender | 0.184 | 0.886 (0.742–1.059) | ||||
| Age | 0.418 | 1.008 (0.989–1.028) | ||||
| ECOG | 0.796 | 1.013 (0.921–1.113) | ||||
| Hypertension | 0.999 | 1.000 (0.834–1.199) | ||||
| Cardiovascular disease | 0.806 | 1.032 (0.805–1.323) | ||||
| Pulmonary disease | 0.795 | 1.038 (0.782–1.379) | ||||
| Diabetes | 0.036 | 1.326 (1.019–1.726) | 0.044 | 1.314 (1.007–1.714) | 0.028 | 1.643 (1.056–2.555) |
| Tumor location | 0.006 | 1.160 (1.044–1.289) | 0.004 | 1.174 (1.052–1.311) | ||
| Primary tumor length | 0.001 | 1.063 (1.024–1.102) | ||||
| Primary tumor volume | < 0.001 | 1.063 (1.024–1.102) | 0.026 | 1.003 (1.000–1.006) | ||
| Clinical T stage | 0.001 | 1.207 (1.079–1.351) | 0.028 | 1.146 (1.015–1.295) | 0.028 | 1.270 (1.026–1.571) |
| Clinical N stage | 0.001 | 1.351 (1.131–1.613) | 0.023 | 1.237 (1.030–1.485) | 0.001 | 1.673 (1.223–2.287) |
| Clinical M stage | < 0.001 | 1.825 (1.308–2.545) | 0.002 | 1.703 (1.209–2.399) | 0.001 | 1.965 (1.295–2.983) |
| GTV dose | 1.398 | 1.000 (1.000–1.000) | ||||
| Technique | 0.676 | 0.964 (0.811–1.146) | ||||
| Treatment pattern | 0.854 | 1.022 (0.811–1.288) | ||||
| Short-term response to RT | 0.001 | 1.263 (1.095–1.457) | 0.003 | 1.243 (1.076–1.435) | ||
PSM Propensity score matching
ECOG Eastern Cooperative Oncology Group scoring